

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification</b> <sup>6</sup> : <b>A01N 1/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/60849</b> <b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)
<b>(21) International Application Number:</b> PCT/US99/11674 <b>(22) International Filing Date:</b> 26 May 1999 (26.05.99)  <b>(30) Priority Data:</b> 60/086,836 26 May 1998 (26.05.98) US  <b>(71) Applicant (for all designated States except US):</b> LIFECELL CORPORATION [US/US]; 3606 Research Forest Drive, The Woodlands, TX 77381 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LIVESEY, Stephen, Anthony [AU/AU]; 104 Napoleon Street, Eltham, VIC 3095 (AU). BURNETT, Michael, Brian [US/US]; 1414 Corral Drive, Houston, TX 77090 (US). CONNOR, Jerome [US/US]; 4 Cinnat Chase, The Woodlands, TX 77381 (US). WAGNER, Christopher, Todd [US/US]; 4517 Briarbend Road, Houston, TX 77035 (US).  <b>(74) Agents:</b> WHITE, Carter, J. et al.; Arnold White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> CRYOPRESERVATION OF HUMAN RED BLOOD CELLS		
<b>(57) Abstract</b> <p>A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence of the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

**CRYOPRESERVATION OF HUMAN RED BLOOD CELLS**

Priority of provisional application Serial Number 60/086,836 Filed: May 26, 1998 is claimed.

**BACKGROUND OF THE INVENTION**

5 Blood is composed of plasma and cellular constituents and plays a prominent role in several key physiological systems of the human body, including immunology, hemostasis, and tissue oxygenation. Movement of the respiratory gases oxygen (O<sub>2</sub>) and carbon dioxide (CO<sub>2</sub>) is the chief function of erythrocytes or red blood cells. This facilitated movement of O<sub>2</sub> and CO<sub>2</sub> is carried out by hemoglobin, an iron-containing, multi-subunit protein contained within red blood  
10 cells. The necessity for encapsulating hemoglobin within the red blood cell is twofold. First, hemoglobin has very specific binding parameters to ensure delivery of these critical molecules to the proper sites. By regulating the concentration of cofactors and free ions, the red blood cell provides the proper environment for optimum uptake and release of O<sub>2</sub>. Secondly, free heme has toxicity effects on both the renal and hepatic systems and can lead to conditions such as  
15 hemoglobinuria.

The red blood cell structural components which confine the hemoglobin are comprised of the membrane bilayer and the cytoskeleton. The membrane itself contains choline and amino phospholipids, cholesterol, and integral membrane proteins. Along the inner surface of the membrane lies the cytoskeleton. This mesh-like skeleton is composed of long, filamentous  
20 spectrin molecules joined together at foci of F-actin and protein 4.1 complexes. This cytoskeletal mesh is linked to the membrane through protein-protein interactions such as the ankyrin/protein 4.2 mediated connection of spectrin and the integral membrane protein Band 3, and possibly via direct protein-lipid interactions. Through these connections, the cytoskeleton provides the red blood cell its stability and shape. In the absence of proper binding within the  
25 cytoskeletal mesh or the connection of the cytoskeleton to the membrane, a critically weakened red blood cell results. Several human diseases have been identified stemming from either an absence of a specific protein or a defective protein interaction. Most of these defects lead to morphologically abnormal red blood cells and severe hemolytic anemias.

A wide variety of injuries and medical procedures require the transfusion of whole blood  
30 or a variety of blood components. Blood transfusions are routinely used to increase oxygen

- 2 -

delivery capacity and circulatory volume in patients. Safe, quick, and easy access to transfusable red blood cell units is not only important for trauma victims with massive blood loss, but also for patients undergoing elective surgery or who have diseases, such as several types of hereditary hemolytic anemias, which result in a loss of circulating red blood cells. The ability to store red blood cells for extended time periods ensures that a supply of transfusable red blood cells will be available when needed. Potential uses include storage of unique serotypes, units intended for autologous transfusion and stockpiling general blood types for emergency situations. Limitations in the current storage methodologies have led, in part, to occasional shortages of blood supply, resulting in postponement of elective surgeries and calls for donations from blood banks and hospitals.

Currently, two methods are approved for extended storage of red blood cells. The majority of red blood cell units are stored in citrate phosphate-dextrose at 4°C. For example, when donor blood is received at a processing center, erythrocytes are separated and stored by various methods, generally as a unit of packed erythrocytes having a volume of from 200 to 300 ml and a hematocrit value of 70 to 90. However, due to metabolic depletion and subsequent physical degradation, these cells may be stored no longer than 42 days. Furthermore, while 70% of these stored cells remain in circulation following transfusion, true O<sub>2</sub> delivery capability has not been demonstrated.

During storage, human red blood cells undergo morphological and biochemical changes, including decreases in the cellular level of adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG), changes in cellular morphology, and progressive hemolysis. The concentration of ATP, after a brief initial rise, progressively declines to between 30 and 40% of its initial level after six weeks of storage. Morphological changes occur during storage, ultimately leading to the development of spicules which can bud off as vesicles, radically changing the surface-to-volume ratio of the cells and their ability to deform on passing through narrow channels. The fluidity of the cell membrane of red cells, which is essential for the passage of red cells through the narrow channels in the spleen and liver, is loosely correlated with the level of ATP. The concentration of ATP and the morphology of red cells serve as indicators of the suitability of stored cells for transfusion.

- 3 -

The second method is frozen storage at -80°C using 40% (w/v) glycerol as a cryoprotectant. However, this additive penetrates the membranes of many biological cells and possesses unwanted properties when infused into humans. While this method can be used for up to 10 years of storage, the glycerol must be washed out prior to transfusion. The washing  
5 procedure utilizes costly equipment and is time and labor intensive. Additionally, a significant level of hemolysis (10-15% typically) occurs during the wash procedure. Finally, since this procedure is also considered to compromise the sterility of the red blood cell units, post-wash storage is significantly limited. Consequently, this method of storage is only used for blood with extremely rare factor types and autologous and directed donation units which will not be used  
10 within a 42 day period. As of 1992, the most recent data available, approximately 14% (nearly 2 million units) of the available supply of transfusable red blood cells were discarded. The ability to cryopreserve red blood cells without the added expense and time of washing, or at least reducing the number of washing cycles necessary, would enable salvage of a significant percentage of these discarded units, thereby providing a further buffer against blood product  
15 shortages.

Current theories of red blood cell cryopreservation consider ice formation and propagation to be the primary, if not the sole factor affecting cell recovery and viability following storage. Consequently, investigation of methods to cryopreserve red blood cells only consider slight variations of traditional cryoprotectant methodologies. Prior methods for the  
20 preservation, storage, and transfusion of red blood cells are explained in Horn, Sputtek, Standl, Rudolf, Kuhn, and Esch, Transfusion of Autologous, Hydroxyethyl Starch-Cryopreserved Red Blood Cells, *Anesth. Analg.* 1997; 85; 739-745. However, temperature-induced modulation of cellular biochemistry is a well recognized phenomenon by experts in this field. The descriptions herein provide methods of utilizing the red blood cell biochemistry to overcome cold-induced  
25 imbalances which would normally lead to cellular hemolysis following cryopreservation. Through these methods, the level of non-specific cryoprotection against ice formation may be reduced.

Two general procedures are currently available for the frozen preservation of living cells in terms of the cryoprotectant used. One utilizes the addition of high concentrations of low

- 4 -

molecular weight penetrant solutes. Due to toxicity and osmotic problems, specialized equipment and techniques are required to remove the solutes following thawing. The second utilizes high molecular weight polymers which do not enter the cells. Post-thaw processing in this case is logistically simpler but storage must be at very low temperature, typically in liquid nitrogen. The formation of ice, which is a prime concern in any method of cell cryopreservation, is initiated by ice crystal nuclei. As the temperature falls and water crystallizes to ice, the cell is progressively dehydrated and at some point cell injury results. The nature of the dehydration injury is believed to be the result of membrane stresses leading to membrane rupture. This form of injury can be prevented by the addition of solutes at a multi-molar concentration so that the amount of ice formed is insufficient to result in damaging cell dehydration .

For many years it has been known that certain molecules may be cryoprotective. It is necessary for these penetrating cryoprotectants to reduce the amount of extracellular ice formed and thereby reduce cell dehydration, while at the same time increasing the intracellular concentration to make intracellular crystallization less likely. Such a solute, to be useful, must be non-toxic at high concentration and must freely penetrate the cell. Both glycerol and dimethylsulfoxide (DMSO) have been used for this purpose. Glycerol is remarkably non-toxic at high concentrations but penetrates cell membranes slowly and is therefore difficult to introduce and remove. Dimethylsulfoxide penetrates rapidly but becomes increasingly toxic as concentrations exceed 1M (about 7%). Large molecular weight polymers, such as polyvinylpyrrolidone (PVP), dextran, and more recently hydroxyethyl starch (HES), do not enter the cell, and the mechanism by which they confer cryoprotection has been the subject of speculation.

As stated above, in order to prolong the storage of red blood cells it is necessary to store the cells or treat them in some manner that prevents a decline in ATP, and, if possible, 2,3-diphosphoglycerate (2,3-DPG), in addition to protection against ice crystal damage. Typically, such solutions contain phosphate, glucose, and adenine which function to prolong shelf-life by maintaining the level of ATP in the cells. In addition, glycolytic activity is enhanced in red blood cells if the intracellular pH measured at 4°C is about 7.4. The effective osmolality of the suspending solution is another factor of importance in extending red cell storage time. It has

- 5 -

been shown that hypotonically induced increases in mean cell volume substantially reduce hemolysis and improves red cell morphology during storage. Although the mechanism has not been proven, it is possible that osmotic swelling increases cell surface tension, thereby opposing the shape changes usually associated with stored red cells. Although the hypotonicity of the additive solution is limited by the danger of hemolysis during the addition of the solution, red cells, which are normally bi-concave disks, can swell to nearly twice their normal volume at an external osmolality of approximately 170mOsm before they hemolyze. If the additive solution is too hypotonic, the red cells will burst (hemolyze). As a result, solutions that are too hypotonic cannot be used. While maintenance of ATP and 2,3-DPG are generally thought of with reference to 4°C storage, maintaining the concentration of these metabolites is important for post-thaw storage. For the effects on ATP levels, hemolysis, potassium leakage, and shedding of microvesicles, on the maintenance and storage of red blood cells, see Greenwalt, Rugg, and Dumaswala, The Effect of Hypotonicity Glutamine, and Glycine on Red Cell Preservation, Transfusion 1997; 37; 269-276.

The goal of extended red blood cell storage is to maintain the metabolic and morphologic characteristics so that the *in vivo* parameters (oxygen delivery capacity and circulatory half-life) are comparable to fresh, non-frozen red blood cells. Additionally, the level of hemolysis during the storage cycle must remain within acceptable levels to allow direct transfusion of the thawed red blood cell unit without complications from hemoglobin toxicity. These goals can be accomplished using the method of this invention. The method described herein provides the advantages of both currently approved storage methods - extended storage time in the frozen state and immediate availability as in refrigerated storage.

Hospitals and blood banks would greatly benefit from a directly-transfusable frozen red blood cell product. Most current investigational approaches to accomplish this attempt to merely replace glycerol with a non-toxic, transfusable cryoprotectant. However, results have shown that most cryoprotectants need to be used at concentrations which may not be transfused or their protective qualities are not enough to maintain hemolysis at acceptable levels for transfusion. Additionally, most procedures require storage at -193°C in liquid nitrogen vapor. This would be

- 6 -

expensive and difficult to incorporate into current blood banking procedures, making extended storage at temperatures below -80°C impractical.

The invention described herein addresses the noted problems of storage, morphological changes, metabolic changes, and long term functional effectiveness of red blood cells. Further, the present invention achieves unexpected and surprising results in the preservation of red blood cells through treating with the compositions and methods of this invention and which previously would have been considered impossible.

### SUMMARY OF THE INVENTION

This invention provides a method for storing red blood cells in the frozen state at subzero temperatures (-10° to -193°C) such that the resulting thawed red blood cell unit contains viable cells. Specifically, this is accomplished through a combination of biochemical stabilization and cryoprotectant solution. A biochemical stabilizing reagent is one that provides no traditional cryoprotection, in that it alone does not diminish the formation or quantity of ice during the freezing process at the concentration used. In the event that the combined cryoprotectant solution is composed of transfusable cryoprotective reagents, the resulting thawed red blood cell unit is directly transfusable. In all circumstances, incorporating biochemical stabilizing technology allows cryopreservation of red blood cells utilizing concentrations of cryoprotectants lower than would be necessary in the absence of biochemical stabilization.

Biochemical stabilization involves the addition of reagents which target specific red blood cell components and biochemical pathways susceptible to damage during the freeze/thaw cycle. Stabilization with these reagents renders the cells partially resistant to freeze/thaw-induced damages, which ultimately results in hemolysis. Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity, and integrity of the cytoskeletal structure. Additionally, specific second messenger pathways, such as the cyclooxygenase, lipoxigenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly through regulation of specific messenger molecules, including cyclic-adenosine monophosphate (c-AMP), cyclic- guanine monophosphate (c-GMP), intracellular calcium, inositol triphosphate, and diacylglycerol.



- 7 -

More specifically, a single reagent or combination of reagents may be added to red blood cell units to target each of the above items. For example, reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride mediated inhibition of the  $\text{Na}^+/\text{H}^+$  exchanger. Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose. Ionic distribution can be regulated through activation or inhibition of specific ion pumps. Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the  $\text{K}^+/\text{Cl}^-$  co-transporter with bumetanide. The cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine. Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of Taxol, [2aR-[2a $\alpha$ ,4 $\beta$ ,4a $\beta$ ,6 $\beta$ ,9 $\alpha$  ( $\alpha$ R\*,  $\beta$ S\*,11 $\alpha$ ,12 $\alpha$ ,12a $\alpha$ ,12b $\alpha$ )]- $\beta$ -(Benzoylamino)-  $\alpha$ -hydroxybenzenepropanoic acid 6, 12b-bis(acetyloxy)-12 - (benzoyloxy) - 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a, 8, 13,-13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca [3,4] benz-[1,2-b]oxet-9-yl-ester, or cytochalasins or spectrin stabilization with polyamines. Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).

In addition to biochemical stabilization, cryoprotectants are used to protect the red blood cell unit from damage by ice crystal formation during the freeze/thaw cycle. The cryoprotectants may be used individually or as mixtures made up of penetrating and/or non-penetrating compounds. Examples of potential cryoprotectants include, but are not limited to dimethylsulfoxide, polyvinyl pyrrolidone, dextran, maltodextrins, 2,3-butanediol, hydroxyethyl starch, polyethylene glycol and glucose and other carbohydrates.

- 8 -

In one embodiment for preserving human red blood cells the method includes drawing a volume of packed red blood cells in ADSOL, a currently licensed additive solution sold by Baxter Travenol, using standard blood banking protocols. The ADSOL is removed by centrifugation, and a volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents is added. The red blood samples containing cryoprotectants are submerged in liquid nitrogen for freezing and immediately transferred to a -80°C freezer for extended storage. Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity and integrity of cytoskeletal structure. Additionally, specific second messenger pathways, such as the cyclooxygenase, lipoxxygenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly through regulation of specific messenger molecules, including c-AMP, c-GMP, intracellular calcium, inositol triphosphate, and diacylglycerol. In one preferred embodiment the biochemical reagents are present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle and even more preferably have concentrations of about 500µM nifedipine, about 20µM cytochalasin B, about 500µM Taxol, about 5mM pentoxifylline, and about 25µg/ml flurbiprofen. The biochemical reagents are present in 2.5% DMSO as a carrier agent. All conditions contain 7.5% dextran (Dex; 40,000 MW), 2% polyvinyl pyrrolidone (PVP; 40,000 MW), 5% hydroxyethyl starch, and 5% polyethylene glycol. The low, transfusable concentrations of cryoprotectants can work in combination to protect the red blood cells during cryopreservation better than any single cryoprotectant alone. Moreover, the addition of the reagents and the biochemical modulation with the low concentrations of transfusable cryoprotectants works in combination to further protect the red blood cells during cryopreservation. An alternative method is to add the isotonic saline or preservative solution containing the biochemical reagents and a volume of Glycerolyte 57 (Fenwall) , preferably about 20% glycerol and freeze the bags at -80°C. The additives used include nicotinamide, nikethamide, nifedipine, pentoxifylline, and flurbiprofen. The 20% glycerol with the addition of the biochemical additives reduces the level of hemolysis and meets the criteria for a transfusable blood unit based on the overall hemolysis and residual free hemoglobin levels.

- 9 -

Thus, one embodiment of the present invention is a red blood cell storage composition including a red blood cell composition and a composition of biochemical stabilization reagents. In such an embodiment the biochemical reagents should be present at a concentration so as to permit decreased hemolysis during the freeze-thaw cycle and increased *in vitro* functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents.

In yet another embodiment of the present invention, a red blood cell composition is formed comprising red blood cells, a composition of red blood cells and biochemical reagents, and a combination of one or more cryoprotective agents.

Another embodiment is directed to a human red blood cell composition comprising human red blood cells, a composition of red blood cells and biochemical reagents. Reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride inhibition of the  $\text{Na}^+/\text{H}^+$  exchanger. Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose. Ionic distribution can be regulated through activation or inhibition of specific ion pumps. Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the  $\text{K}^+/\text{Cl}^-$  co-transporter with bumetanide. The cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine. Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of TAXOL or cytochalasins or spectrin stabilization with polyamines. Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP). The biochemical

- 10 -

reagents are present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle.

### **DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

The biochemical stabilization of this invention is based on the application of specific effectors, which target specific aspects of cellular biochemistry to protect cells against specific modes of damage. The method of cryopreservation is such that the stored cells may be directly transfused following thaw, by combining biochemical reagents and low concentrations of transfusable cryoprotectants. The biochemical stabilization involves regulation of the metabolic, ionic, cytoskeletal, and membrane component, rendering the treated red blood cells less susceptible to damage induced during freezing and thawing at temperatures between -10°C to -193°C.

In one embodiment, specific cellular effectors are nifedipine, cytochalasin B, Taxol, pentoxifylline, flurbiprofen, nikethamide, ribose, and trehalose. These modifiers are added to the packed red blood cells and the preservative solution. Each of the modifiers affects different specific cellular biochemistry. In one aspect of the present invention, nifedipine an inhibitor acting through the calcium cascade controls calcium, while, cytochalasin B and Taxol are cytoskeletal modifiers and provide stabilization to the cell through actin stabilization. In another aspect of the present invention, membrane stabilization and fluidity may be controlled through pentoxifylline, a membrane modifier. Ribose is added to prevent oxidative damage to the cell by stimulation of the hexose monophosphate pathway.

The second messenger effectors have been demonstrated to provide biochemical stabilization to the red blood cells either individually or in combination with others. More, importantly, the addition of these reagents allows biochemical modulation to enhance cryoprotection at lower glycerol concentrations which normally result in nearly 100% of the red blood cells being inadequately protected during the freeze/thaw and washing cycles. In describing the chemicals which have shown utility as effectors of the second messenger pathways, it must be understood that the actual chemicals mentioned together with functionally equivalent materials are intended to be within the scope of this invention. Chemicals that are known to applicants to have known or demonstrated utility as modifiers have been specifically

- 11 -

set forth in the instant application. However, it is intended that the scope of the application be extended to other functionally effective chemicals, both existing chemicals and chemicals yet to be discovered.

Certain chemicals which are thought to be functionally equivalent materials for the modifier acting through the second messenger pathway are those selected from cyclic-adenosine monophosphate, c-(AMP), cyclic-guanine monophosphate, c-(GMP), intracellular calcium, inositol triphosphate, and diacylglycerol. Functionally equivalent modifiers acting through the cyclic nucleotide regulated second messenger pathway are those selected from adenosine, sodium nitroprusside, and other nitric oxide donors. Materials thought to be functionally equivalent to the modifier of intracellular concentrations of ATP are those selected from glucose, pyruvate, and inorganic phosphate, as well as ATP-depleting ATPases such as amiloride. Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of functionally equivalent antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose. Ionic distribution can be regulated through activation or inhibition of specific ion pumps. Functionally equivalent modifiers of calcium may be selected from nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the  $K^+/Cl^-$  co-transporter with bumetanide. The cyclooxygenase and lipoxygenase pathways may be regulated through the addition of functionally equivalent modifiers of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine, which are also functionally equivalent reagents. Reagents which are functionally equivalent regulators of membrane stabilization and fluidity are pentoxifylline, nicotinamide or amantadine, while for the regulation of cytoskeletal structure through actin stabilization, the reagents are TAXOL or cytochalasins and for spectrin stabilization, polyamines. Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of functionally equivalent adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).

- 12 -

The post-thaw life of the red blood cells after cryopreservation may be successfully extended by storing the cells at -80°C with the biochemical reagents of this invention. When red blood cells were stored for 3-7 days in a -80°C freezer and thawed at 37°C in a water bath and analyzed for post-storage hemolysis, as compared to red cells stored in glycerol concentrations alone, the percentage of hemolysis was as follows: 14.36% with nifedipine, 15.01 % with Taxol and cytochalasin B, 11.46% with nifedipine, pentoxifylline, and flurbiprofen, and 11.66% with nifedipine, cytochalasin, and Taxol. These results compare favorably to enhance cryoprotection when compare to glycerol concentrations which normally result in nearly 100% of the red blood cells being inadequately protected during the freeze/thaw and washing cycles.

To perform the experiment, a packed red blood cell unit in ADSOL was obtained using standard blood banking protocols. The ADSOL was removed by centrifugation and a volume of preservation solution containing the desired cryoprotectants and biochemical reagents was added. The final concentrations of cryoprotectant used were 7.5% dextran, 2% polyvinyl pyrrolidone, 5% hydroxyethyl starch, and 2.5% dimethyl sulfoxide as a biochemical reagent carrier. Reagents used included 500µM nifedipine, 20µM cytochalasin B, 500µM Taxol, 5mM pentoxifylline and 25µg/ml flurbiprofen. After the ADSOL was removed and the preservation solution was added, 50 ml of red cells was placed into freezing bags having a maximum volume of 150ml. An equal volume was added to each of the bags. The bags were plunge frozen and stored at -80°C for 2-7 days and thawed by submersion a 37°C water bath for 10 minutes. Level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. This biochemical reagent mixture is able to be directly transfused following storage.

Storing red blood cells at -10°C to -193°C requires the addition of a cryoprotective agent, such as dimethyl sulfoxide (DMSO). Cryoprotective agents such as DMSO are polar molecules which penetrates the cell membrane and serves to preserve cell viability during the cryopreservation process. In addition to DMSO, other cryoprotective agents used in this invention include polyvinyl pyrrolidone, dextran maltodextrins, 2,3-butanediol, hydroxyethyl starch, polyethylene glycol, glucose, and combinations thereof. The success of cryopreservation with certain water soluble molecules which do not permeate the cells has been reported, however, the exact mechanism for this success is unknown. It has been speculated that this

- 13 -

phenomenon including that the polymers protect cells by lowering extracellular salt concentrations at subfreezing temperatures just as penetrating cryoprotectants do, or, that the polymers might adsorb to cells and thus protect the membrane in some way. It has also been speculated that during freezing an electrolyte gradient develops from inside to outside the cells causing an electrolyte leakage which relieves osmotic stress. The cryoprotectants may be used individually or as mixtures made up of penetrating and/or non-penetrating compounds in transfusable concentrations to protect the red blood cells from damage by ice crystal formation during the freeze/thaw cycle.

For example, it can be shown by a comparison of the following percentages of thaw hemolysis that combinations of transfusable concentrations of cryoprotectants allow increased protection from hemolysis than a single cryoprotective agent: 7.5% dextran, 11.19% hemolysis; 2% polyvinyl pyrrolidone, 47.39% hemolysis; 5% hydroxyethyl starch, 43.17% hemolysis; 7.5% dextran and 2% polyvinyl pyrrolidone, 6.42% hemolysis; 7.5% dextran and 5% hydroxyethyl starch, 8.56% hemolysis; 2% polyvinyl pyrrolidone and 5% hydroxyethyl starch, 23.46% hemolysis, and finally 7.5% dextran, 2% polyvinyl pyrrolidone, and 5% hydroxethyl starch, 4.44% hemolysis.

A red blood cell storage composition of the present invention, includes a storage composition, a composition of red blood cells, and a composition of biochemical reagents, the reagents present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle and in a concentration to increase the *in vitro* functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents. As the term is used herein and in the claims the "storage composition," is intended to mean a pharmacologically inert fluid into which the red blood cells may be suspended and which does not adversely affect the preservation abilities of the compositions disclosed herein, for example physiological saline. Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity and integrity of cytoskeletal structure. Additionally, specific second messenger pathways, such as the cyclooxygenase, lipoxygenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly

- 14 -

through regulation of specific messenger molecules, including cyclic-adenosine monophosphate, (c-AMP), cyclic-guanine monophosphate, (c-GMP), intracellular calcium, inositol triphosphate, and diacylglycerol.

In one preferred embodiment the modifiers acting through the second messenger pathway is selected from cyclic-adenosine monophosphate, (c-AMP), cyclic guanine monophosphate, (c-GMP), intracellular calcium, inositol triphosphate, and diacylglycerol. Reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride inhibition of the  $\text{Na}^+/\text{H}^+$  exchanger. Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose. Ionic distribution can be regulated through activation or inhibition of specific ion pumps. Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the  $\text{K}^+/\text{Cl}^-$  co-transporter with bumetanide. The cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine. Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of TAXOL or cytochalasins or spectrin stabilization with polyamines. Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).

In another preferred embodiment, the biochemical reagents are: nifedipine in a concentration of about 500 $\mu\text{M}$ , cytochalasin B in a concentration of about 20 $\mu\text{M}$ , Taxol in a concentration of about 500 $\mu\text{M}$ , pentoxifylline in a concentration of about 5mM, and flurbiprofen in a concentration of about 25 $\mu\text{g/ml}$ . The blood cell storage composition of the present embodiment may further include a cryoprotective agent, the cryoprotective agent being selected



- 15 -

from dimethyl sulfoxide, polyvinyl pyrrolidone, dextran maltodextrins, 2,3-butandiol, hydroxyethyl starch, polyethylene glycol, glucose, and combinations thereof. Preferably, the cryoprotective agents are: dextran in a concentration of about 7.5%; polyvinyl pyrrolidone in a concentration of about 2%; dimethyl sulfoxide in a concentration of about 2.5%; hydroxyethyl starch in a concentration of about 5%, and polyethylene glycol in a concentration of about 5%. The prolonged storage of the red blood cells should be carried out at a temperature below the red cells' normal physiological temperature. In one embodiment, the temperature is from about -10°C to about -193°C. In another embodiment the temperature below the red blood cells' normal physiological temperature is about -80°C.

The following examples demonstrate the ability of biochemical stabilization to enhance the preservation of red blood cells at temperatures less than -10°C. Both glycerol-based and transfusable, polymeric-based cryoprotectant solutions are described.

The examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the concept and scope of the invention.

#### EXAMPLE 1

The following example demonstrates the damage induced during the freeze/thaw cycle when the glycerol concentration is decreased. A significant percentage of the hemolytic damage is shown to be reversed by the addition of a preservative solution containing adenine, glutamine, sodium chloride, mannitol, and dextrose, with the essential additive being dextrose, and final concentrations of 5 mM pentoxifylline and 25µg/ml flurbiprofen in DMSO as a carrier.

Specifically, 50ml of packed red blood cells was added to a PVC freezing bag with a maximum volume of 150ml. Isotonic saline or preservative solution containing the additional biochemical reagents pentoxifylline and flurbiprofen was mixed with the red blood cells. A volume of Glycerolyte 57 (Fenwall) was added slowly until the final concentration of glycerol

- 16 -

was achieved. The total volume of all additions was 50 ml, making the final concentration of the red blood cell unit 100ml. The PVC bags were frozen at -80°C for 2-7 days and thawed by submersion in a 37°C water bath for 10 minutes. The level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. The levels of thaw hemolysis are shown below  
5 in TABLE 1.

**TABLE 1**  
**LEVELS OF THAW HEMOLYSIS**

	% Hemolysis
40% Glycerol	1.91
10 30% Glycerol	3.53
20% Glycerol	35.29
20% + Additives	14.87

These results confirm the loss of red blood cell protection at reduced glycerol  
15 concentrations and the ability of biochemical reagents to provide cryoprotection at glycerol concentrations which alone are unable to completely protect red blood cells during cryopreservation.

#### EXAMPLE 2

20 The following example further demonstrates the damage induced during the freeze/thaw cycle when the glycerol concentration is decreased, after red blood cells are frozen and stored at -80° C. Fifty ml of packed red blood cells were added to a PVC freezing bag. Isotonic saline or preservative solution containing the additional biochemical reagents of interest was mixed with the red blood cells. The samples were treated as follows prior to freezing at -80°C:

- 25
1. 40% Glycerol
  2. 20 % Glycerol
  3. Nicotinamide
  4. Nikethamide, Nifedipine
  5. Nikethamide, Nifedipine, Pentoxifylline, Flurbiprofen

- 17 -

## 6. Nicotinamide Nikethamide, Nifedipine, Pentoxifylline, Flurbiprofen

A volume of Glycerolyte 57 (Fenwall) was added slowly until the final concentration of glycerol was achieved. The total volume of all additions was 50 ml, making the final volume of the red blood cell unit 100 ml. The PVC bags were frozen at -80° C for 2-7 days and thawed by submersion in a 37° C water bath for 10 minutes. The level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. Additionally, the glycerol was removed from the thawed red blood cell units by serial dilution with saline similar to blood bank protocols. The overall hemolysis and the final residual free hemoglobin levels were also determined.

TABLE 2 compares 40% glycerol to 20% glycerol and 20% glycerol with the indicated additives. The additives used included nicotinamide, nikethamide, nifedipine, pentoxifylline, and flurbiprofen. The results of 20% glycerol with all additives meet the criteria for a transfusable blood unit based on the overall hemolysis and residual free hemoglobin levels. These results confirm the loss of red blood cell protection at reduced glycerol concentrations and the ability of biochemical reagents to provide cryoprotection at glycerol concentrations which alone are unable to completely protect red blood cell during cryopreservation.

**TABLE 2**

<b>Biochemical Stabilization with Glycerol Based Cryoprotectant</b>			
Condition	Thaw	Hemolysis (%) Overall	Final
40% Glycerol	2.01	14.1	0.45
20% Glycerol	9.39	41.48	1.09
Nicotinamide	8.13	22.93	0.43
Nikethamide/Nifedipine	9.65	37.23	0.8
Nikethamide/Nifedipine Pentoxifylline/Flurbiprofen	9.94	34.48	0.69
Nicotinamide Nikethamide/Nifedipine Pentoxifylline/Flurbiprofen	9.07	17.84	0.33

**EXAMPLE 3**

The following experiment demonstrates the ability of biochemical addition to provide protection against damage during cryopreservation. The model used is a reduced glycerol cryopreservation system. 10%(w/v) glycerol is added to the unit prior to freezing at -80°C. A significant level of hemolysis occurs so that protection by the added reagent may be distinguished.

A single unit of packed red blood cells in ADSOL was obtained using standard blood banking protocols. The ADSOL was removed by centrifugation and a volume of preservation solution was added until the resulting hematocrit was about 50%. From this red blood cell unit 50 ml of red cells was placed into each of 3 PVC freezing bags having a maximum volume of 150ml. An equal volume (50ml) was added to each of the bags composed of the above preservation solution and the experimental conditions. The final composition of the first bag was 10% (w/v) glycerol. The second contained 10% (w/v) glycerol and 2.5% DMSO and 500  $\mu$ M nifedipine. The bags were frozen at -80°C for 2-7 days and thawed by submersion in a 37°C water bath for 10 minutes. The level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. Additionally, the glycerol was removed from the thawed red blood cell units by serial dilution with saline similar to blood bank protocols. The overall hemolysis was also determined. The results are shown below in TABLE 3.

**TABLE 3**  
**OVERALL HEMOLYSIS**

	% Hemolysis	
	Thaw	Overall
10% Glycerol	61.71 $\pm$ 1.26	93.62 $\pm$ 1.28
w/2.5% DMSO	59.45 $\pm$ 0.90	81.86 $\pm$ 2.72
w/500 $\mu$ M Nifedipine	55.12 $\pm$ 1.58	70.94 $\pm$ 2.96

- 19 -

This example further confirms the ability of biochemical modulation to enhance cryoprotection at glycerol concentrations which normally result in nearly 100% of the red blood cells being inadequately protected during the freeze/thaw cycles.

5        EXAMPLE 4

This example demonstrates the ability of biochemical stabilization to enhance red blood cell cryopreservation in conjunction with a glycerol based cryoprotectant. An aliquot of blood was transferred to a PVC storage bag, to which any experimental agents were added. Glycerol was then added until the desired final glycerol was achieved. This unit was frozen at -80°C,  
10 stored and thawed in a 37°C water bath for 10 minutes. The glycerol was removed by serial dilution and centrifugation with 12%, 1.6% and 0.9% saline until the residual free hemoglobin is less than 2% of the total hemoglobin content.

TABLE 4 show results following the desired procedure. The values indicate the percent hemolysis in the thawed sample, the overall amount of hemolysis following the wash and the  
15 percent of residual free hemoglobin in the final sample. Hemolysis is calculated as the ratio of free hemoglobin to the total hemoglobin content in the sample.

- 20 -

**TABLE 4**  
**BIOMEDICAL STABILIZATION**  
**WITH GLYCEROL-BASED CRYOPROTECTANT**

	Condition	% Hemolysis	
		Thaw	Overall
5	40% Glycerol	1.9	6.1
	20% Glycerol with Control	37.9	52.0
	20% Glycerol with Pentoxifylline	20.6	27.6
	20% Glycerol with Nifedipine	20.2	38.5
10	20% Glycerol with Amiloride	23.6	58.7
	20% Glycerol with Flurbiprofen	22.9	46.9
	20% Glycerol with Pentoxifylline Flurbiprofen	12.5	19.3
	20% Glycerol with Nikethamide	11.0	17.0
15	20% Glycerol with Nicotinamide	4.2	7.8
	20% Glycerol with Nikethamide Nifedipine Nicotinamide	7.8	14.0

#### EXAMPLE 5

The following example demonstrates that biochemical stabilization using non-cryoprotective reagents reduces the level of hemolysis when using alternative polymeric reagents as the primary cryoprotectants, when red blood are plunge frozen and subsequently stored at -80° C. A volume of packed red blood cell was mixed with an equal volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents. The final concentrations of cryoprotectants used were 7.5% dextran (Dex; 40,000 MW) and 2% polyvinyl pyrrolidone (PVP; 40,000 MW). The red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for 3 minutes to freeze and immediately transferred to a -80° C freezer for extended storage. Following storage for 3-7 days, the samples

- 21 -

were thawed at 37° C in a water bath, and the level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. Additionally, the glycerol was removed from the thawed red blood cell units by serial dilution with saline similar to blood bank protocols. The overall hemolysis and the final residual free hemoglobin were also determined.

5           TABLE 5 shows the biochemical stabilization with a polymeric based cryoprotectant and the resulting percent hemolysis. All samples contained 7.5% Dex and 2% PVP, 2.5% dimethyl sulfoxide as a biochemical carrier, prior to storage at -80° C, in addition to the indicated additive as follows:

1.       DMSO
- 10       2.       Nifedipine
3.       Cytochalasin, Taxol
4.       Nifedipine, Pentoxifylline, Flurbiprofen
5.       Nifedipine, Cytochalasin, Taxol

          Reagents used include 500 µM nifedipine, 20µM cytochalasin B, 500µM Taxol, 5 mM  
15   pentoxifylline, and 25 µg/ml flurbiprofen in several combinations.

          This example further confirms the ability of biochemical modulation to enhance cryoprotection at glycerol concentrations which normally result in nearly 100% of the red blood cell being inadequately protected during the freeze/thaw and washing cycles. The biochemical stabilization with a polymeric cryoprotectant and resulting percentage hemolysis is displayed in  
20   TABLE 5.

- 22 -

**TABLE 5**

<b>Biochemical Stabilization with Polymeric Based Cryoprotectant</b>	
Condition	% Hemolysis
DMSO	23.17 $\pm$ 0.58
Nifedipine	14.36 $\pm$ 0.45
Cytochalasin/Taxol	15.01 $\pm$ .70
Nifedipine Pentoxifylline/Flurbiprofen	11.46 $\pm$ 0.44
Nifedipine/Cytochalasin/Taxol	11.66 $\pm$ 0.37

**EXAMPLE 6**

The following example describes an experiment to measure the biochemical stabilization and the post-thaw hemolytic lesion upon dilution, analogous to transfusion, after red blood cell are plunge frozen and stored at -80° C. This type of storage lesion is not commonly addressed but is observed with most non-glycerol based cryoprotective solutions. A volume of packed red blood cell was mixed with an equal volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents. Using a cryoprotective additive solution (CPA) containing 7.5% dextran (Dex; 40,000 MW) 2% polyvinyl pyrrolidone (PVP; 40,000 MW), 5% hydroxyethyl starch (HES), and 5% polyethylene glycol (PEG), the red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for 3 minutes to freeze and immediately transferred to a -80° C freezer for extended storage. Following storage the thaw samples were split into two aliquots. The first aliquot was analyzed immediately, and the remaining aliquot was incubated at 4° C for 3 hours prior to analysis. The analyzed endpoints included hemolysis in the thawed sample and the additional hemolysis which occurs upon 1:1 dilution with one of 2 different diluent solution, PBS or isotype plasma.

In TABLE 6, the stability of the red blood cells following thaw is seen the thaw hemolysis values and the beneficial effect of 4°C incubation is observed in the dilution induced hemolysis values. Most important is the ability of biochemical additives to enhance the protection during the protocol. The biochemical additives were used to stabilize the cells post-thaw and demonstrate this effect by decreasing the dilution-induces hemolysis. Thus, the



- 23 -

damage to the red blood cells during cryopreservation is shown here to be both partially self-reversible and either preventable or correctable with biochemical additions: The treatment conditions were as follows:

1. CPA only
2. CPA + 50mM Ribose
3. CPA + 50mM Ribose  
50mM Trehalose  
500 $\mu$ M Nifedipine  
5 mM Pentoxifylline  
50 $\mu$ g/ml Flurbiprofen

**TABLE 6**

Biochemical Stabilization Against Post-Thaw Hemolysis					
Condition		Immediate		4°C	
		PBS	Plasma	PBS	Plasma
CPA Only	Thaw (%)	2.15		2.23	
	Dilution (%)	6.39	5.57	4.55	3.73
CPA + Ribose	Thaw (%)	1.62		2.05	
	Dilution (%)	8.94	6.60	5.85	3.85
CPA + All Additives	Thaw (%)	2.71		2.56	
	Dilution (%)	3.53	3.23	2.62	2.26

**EXAMPLE 7**

The following experiment demonstrates the ability of alternative cryoprotectants at low, transfusable concentrations to act in combination to enhance protection against freeze/thaw induced hemolysis.

A single packed red blood cell unit containing ADSOL was obtained and prepared using standard blood banking protocols. The ADSOL was removed by centrifugation and a volume of preservation solution was added. A volume of the resulting red blood cell unit was mixed with

- 24 -

an equal volume of preservation solution containing the desired cryoprotectant(s). The final concentrations of cryoprotectants used were 7.5% dextran (Dex; 40,000 MW), 2% polyvinyl pyrrolidone (PVP; 40,000 MW) and 5% hydroxyethyl starch (HES). The red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for three minutes to freeze and immediately transferred to a -80°C freezer for extended storage. Following storage for 3-7 days, the samples were thawed at 37°C in a water bath, and the level of thaw hemolysis was determined as described as the ratio of free hemoglobin to total hemoglobin. The levels of thaw hemolysis are shown in TABLE 7 below:

**TABLE 7**  
**LEVEL OF THAW HEMOLYSIS**

	<b>% Hemolysis</b>
Dex	11.19±0.38
PVP	47.39±2.42
HES	43.17±10.1
Dex/PVP	6.42±1.38
Dex/HES	8.56±0.82
PVP/HES	23.46±4.84
Dex/PVP/HES	4.44±0.04

This example confirms that extremely low, transfusable concentrations of cryoprotectants can work in combination to protect red blood cells during cryopreservation better than any single cryoprotectant alone.

In view of the above disclosure, one of ordinary skill in the art should understand and appreciate that one illustrative embodiment of the present invention includes a red blood cell storage composition which includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. Preferably the

- 25 -

reagents of the present illustrative embodiment are selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxigenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated second messenger pathway, and combinations thereof. More preferably, the reagents of the present illustrative embodiment are selected such that: the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine; the modifier of antioxidant potential is selected from glutathione, tocopherol, ascorbate,  $\alpha$ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin; the effector of intracellular ionic distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamide, diltiazem, clotrimazole, tetramethylammonium diphenylhydantoin, diisothiocyanatstilbene-2,2'-disulfonic acid, verapamil, amiloride, bumetanide, N-(6-aminoethyl)-5-chloro-1-naphthalene sulfonamide and derivatives thereof; the modifier of membrane fluidity is selected from pentoxifylline, nicotinamide, amantadine, carnitine, palmitoyl carnitine, sphingosine, diethylnicotinamide, (nikethamide), nicotinic acid, trehalose, valinomycin, procaine, tetracaine, rimantadine, propanolol, and protease inhibitors such as leupeptin; the modifier of cytoskeletal structure is selected from TAXOL, cytochalasins, paclitaxel, okadaic acid and polyamines such as spermine, spermidine, or putrescine; the effector of the cyclooxygenase and lipoxigenase second messenger pathways is selected from flurbiprofen, dipyridamole, salicylic acid, and indomethacin; the effector of the hexose monophosphate second messenger pathway is selected from ribose or pyruvate; the effector of the phosphorylation second messenger pathway is selected from H7 (1-[5-isoquinoliny]sulfonyl]-2-methylpiperazine), staurosporin, chelerythrine, and diacylglycerol

- 26 -

palmitoyl carnitine; and the modifier of the cyclic nucleotide regulated second messenger pathway is selected from adenosine, sodium nitroprusside, dibutyl AMP, dibutyl GMP.

The illustrative composition may also be formulated such that the biochemistry altering reagents are combined with one or more cryoprotective agent. In one preferred embodiment, the cryoprotective agent may be a permanent cryoprotectant, preferably the permanent cryoprotectant may be selected from glycerol, dimethyl sulfoxide, 2,3-butandiol, 1,2-propandiol, 1,3-propandiol, polypropylene glycol, N,N-dimethylacetamide, and 1,3,5-trimethyl pentanetriol and combinations thereof. Alternatively, the composition may be formulated such that the cryoprotective agent is a non-permanent cryoprotectant, which preferably may be selected from hydroxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof. A combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants may also be utilized in the formulation of the present illustrative embodiment. When the formulation includes a non-permanent cryoprotectant it is preferred that the non-permanent cryoprotectant have a molecular weight of at least about 5,000 MW.

Another illustrative embodiment of the present invention includes a human red blood cell composition including: red blood cells; a storage composition; and a composition of reagents, wherein the composition of reagents is selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated second messenger pathway, and combinations thereof.

In such an illustrative composition, it is preferred that: the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodoacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine; the modifier of antioxidant potential is selected from

- 27 -

glutathione, tocopherol, ascorbate,  $\alpha$ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin; the effector of intracellular ionic distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamide, diltiazem, clotrimazole, tetramethylammonium  
5 diphenylhydantoin, diisothiocyanatstilbene-2,2'-disulfonic acid, verapamil, amiloride, bumetanide, N-(6-aminoethyl)-5-chloro-1-naphthalene sulfonamide and derivatives thereof; the modifier of membrane fluidity is selected from pentoxifylline, nicotinamide, amantadine, carnitine, palmitoyl carnitine, sphingosine, diethylnicotinamide, (nikethamide), nicotinic acid, trehalose, valinomycin, procaine, tetracaine, rimantadine, propranolol, and protease inhibitors  
10 such as leupeptin; the modifier of cytoskeletal structure is selected from TAXOL, cytochalasins, paclitaxel, okadaic acid and polyamines such as spermine, spermidine, or putrescine; the effector of the cyclooxygenase and lipoxygenase second messenger pathways is selected from flurbiprofen, dipyridamole, salicylic acid, and indomethacin; the effector of the hexose monophosphate second messenger pathway is selected from ribose or pyruvate; the effector of  
15 the phosphorylation second messenger pathway is selected from H7 (1-[5-isoquinolinesulfonyl]-2-methylpiperazine), staurosporin, chelerythrine, and diacylglycerol palmitoyl carnitine; and the modifier of the cyclic nucleotide regulated second messenger pathway is selected from adenosine, sodium nitroprusside, dibutyl AMP, dibutyl GMP.

The illustrative composition may be formulated such that the composition of reagents are  
20 combined with one or more cryoprotective agents. In one such illustrative embodiment, the cryoprotective agent is a permanent cryoprotectant selected from glycerol, dimethyl sulfoxide, 2,3-butanediol, 1,2-propanediol, 1,3-propanediol, polypropylene glycol, N,N-dimethylacetamide, 1,3,5-trimethyl pentanetriol and combinations thereof. In another such illustrative embodiment, the cryoprotective agent is a non-permanent cryoprotectant selected from hydroxyethyl starch,  
25 dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof. Preferably the cryoprotective solution is a combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants. When a non-permanent cryoprotectant is utilized in the formulation, it is preferred that the non-permanent cryoprotectant have a molecular weight of at least 5000 MW.

- 28 -

The illustrative embodiment should be formulated such that the biochemical reagents are present in a concentration so that upon *in vitro* preservation of the red blood cells at a temperature below the red blood cells normal physiological temperature for a period of about 2-7 days, the red blood cells exhibit decreased hemolysis during a freeze-thaw cycle and increased *in vitro* functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents. Thus in one preferred embodiment of the present illustrative embodiment the nifedipine has a concentration of about 500 $\mu$ M, the cytochalasin B has a concentration of about 20 $\mu$ M, the Taxol has a concentration of about 500 $\mu$ M, the pentoxifylline has a concentration of about 5mM, the flurbiprofen has a concentration of about 25 $\mu$ g/ml, the nikethamide has a concentration of about (1% v/v), the ribose has a concentration of about .50mM, and the trehalose has a concentration of about 50mM.

It should also be appreciated that the present invention includes a method for storing human red blood cells including: (a) isolating red blood cells from fresh human blood; (b) forming a red blood cell composition; and (c) storing the resulting red blood cell composition at a temperature below normal human physiological temperature effective to preserve the blood cells for a selected period of time. Preferably the red blood cell composition should be formulated so as to include: red blood cells; a storage composition; and a composition of reagents. The composition of reagents should be selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated messenger pathway, and combinations thereof. In practicing the present illustrative method, the temperature below normal physiological temperature effective to preserve the red blood cells for selected period of time is preferably about -10°C to -193°C, and more preferably is about -80°C.

- 29 -

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described  
5 herein without departing from the concept and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to  
10 be within the concept and scope of the invention as defined by the appended claim.

**CLAIMS:**

1. A red blood cell storage composition comprising a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents.

2. The red blood cell storage composition of claim 1 wherein the reagents are selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated second messenger pathway, and combinations thereof.

3. The red blood cell storage composition of claim 2 wherein:

the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine;

the modifier of antioxidant potential is selected from glutathione, tocopherol, ascorbate,  $\alpha$ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin;

the effector of intracellular ionic distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamide, diltiazem, clotrimizole, tetramethylammonium diphenylhydantoin, diisothiocyanatstilbene-2,2'-disulfonic acid, verapamil, amiloride, bumetanide, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide and derivatives thereof;

the modifier of membrane fluidity is selected from pentoxifylline, nicotinamide, amantadine, carnitine, palmitoyl carnitine, sphingosine, diethylnicotinamide, (nikethamide),



- 31 -

nicotinic acid, trehalose, valinomycin, procaine, tetracaine, rimantadine, propanolol, and protease inhibitors such as leupeptin;

the modifier of cytoskeletal structure is selected from TAXOL, cytochalasins, paclitaxel, okadaic acid and polyamines such as spermine, spermidine, or putrecine;

5 the effector of the cyclooxygenase second messenger pathway is selected from flurbiprofen, dipyridamole, salicyclic acid, and indomethacin;

the effector of the lipoxygenase second messenger pathway is selected from flurbiprofen, dipyridamole, salicyclic acid, and indomethacin;

10 the effector of the hexose monophosphate second messenger pathway is selected from ribose or pyruvate;

the effector of the phosphorylation second messenger pathway is selected from H7 (1-[5-isoquinolinylnsulfonyl]-2-methylpiperazine), staurosporin, chelerythrine, and diacylglycerol palmitoyl carnitine; and

15 the modifier of the cyclic nucleotide regulated second messenger pathway is selected from adenosine, sodium nitroprusside, dibutyl AMP, dibutyl GMP.

4. The composition of claim 2 wherein the biochemistry altering reagents are combined with one or more cryoprotective agent.

5. The composition of claim 4 wherein the cryoprotective agent is a permanent cryoprotectant selected from glycerol, dimethyl sulfoxide, 2,3-butandiol, 1,2-propandiol, 1,3-propandiol, polypropylene glycol, N,N-dimentylacetamide, and 1,3,5-trimethyl pentanetriol and combinations thereof

6. The composition of claim 4 wherein the cryoprotective agent is a non-permanent cryoprotectant selected from hydroxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof.

25 7. The composition of claim 4 wherein the cryoprotective solution is a combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants.

8. The composition of claims 6 or 7 wherein the non-permanent cryoprotectant has a molecular weight of at least about 5,000 MW.

- 32 -

9. A method for the prolonged storage of red blood cells comprised of mixing the red blood cell storage composition of claim 1 with a preparation of red blood cells and storing the resulting mixture at a temperature below the red blood cells' normal physiological temperature.

10. The method of claim 9 wherein the temperature below the red blood cells' normal physiological temperature is from about -10°C to about -193°C.

11. A method for the prolonged storage of red blood cells comprised of mixing the red blood cell storage composition of claim 3 with a preparation of red blood cells and storing the resulting mixture at a temperature below the red blood cells' normal physiological temperature.

12. The method of claim 9 wherein the temperature below the red blood cells' normal physiological temperature is about -80°C.

13. A human red blood cell composition comprising red blood cells;

a storage composition; and

a composition of reagents, wherein the composition of reagents is selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxigenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated second messenger pathway, and combinations thereof.

14. The composition of claim 13 wherein:

the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodoacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine;

the modifier of antioxidant potential is selected from glutathione, tocopherol, ascorbate,  $\alpha$ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin;

- 33 -

the effector of intracellular ionic distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamide, diltiazem, clotrimazole, tetramethylammonium diphenylhydantoin, diisothiocyanatstilbene-2,2'-disulfonic acid, verapamil, amiloride, bumetanide, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide and derivatives thereof;

the modifier of membrane fluidity is selected from pentoxifylline, nicotinamide, amantadine, carnitine, palmitoyl carnitine, sphingosine, diethylnicotinamide, (nikethamide), nicotinic acid, trehalose, valinomycin, procaine, tetracaine, rimantadine, propanolol, and protease inhibitors such as leupeptin;

the modifier of cytoskeletal structure is selected from TAXOL, cytochalasins, paclitaxel, okadaic acid and polyamines such as spermine, spermidine, or putrecine;

the effector of the cyclooxygenase second messenger pathway is selected from flurbiprofen, dipyridamole, salicylic acid, and indomethacin;

the effector of the lipoxigenase second messenger pathway is selected from flurbiprofen, dipyridamole, salicylic acid, and indomethacin;

the effector of the hexose monophosphate second messenger pathway is selected from ribose or pyruvate;

the effector of the phosphorylation second messenger pathway is selected from H7 (1-[5-isoquinoliny]sulfonyl]-2-methylpiperazine), staurosporin, chelerythrine, and diacylglycerol palmitoyl carnitine; and

the modifier of the cyclic nucleotide regulated second messenger pathway is selected from adenosine, sodium nitroprusside, dibutyl AMP, dibutyl GMP.

15. The composition of claim 13 further comprising wherein the composition of reagents are combined with one or more cryoprotective agent.

16. The composition of claim 15 wherein the cryoprotective agent is permanent cryoprotectant selected from glycerol, dimethyl sulfoxide, 2,3-butandiol, 1,2-propandiol, 1,3-propandiol, polypropylene glycol, N,N-dimethylacetamide, 1,3,5-trimethyl pentanetriol and combinations thereof.

- 34 -

17. The composition of claim 15 wherein the cryoprotective agent is a non-permanent cryoprotectant selected from hydroxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof.

18. The composition of claim 15 wherein the cryoprotective solution is a combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants.

19. The composition of claim 15 wherein the non-permanent cryoprotectant has a molecular weight of at least 5000 MW.

20. The composition of claim 14 wherein the nifedipine has a concentration of about 500 $\mu$ M, the cytochalasin B has a concentration of about 20 $\mu$ M, the Taxol has a concentration of about 500 $\mu$ M, the pentoxifylline has a concentration of about 5mM, the flurbiprofen has a concentration of about 25 $\mu$ g/ml, the nikethamide has a concentration of about (1% v/v), the ribose has a concentration of about 50mM, and the trehalose has a concentration of about 50mM.

21. The composition of claim 14 wherein the biochemical reagents are present in a concentration so that upon in vitro preservation of the red blood cells at a temperature below the red blood cells normal physiological temperature for a period of about 2-7 days, the red blood cells exhibit decreased hemolysis during a freeze-thaw cycle and increased *in vitro* functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents.

22. A method for the prolonged storage of red blood cells comprising storing the red blood cells in a composition of claim 21 at a temperature below the red blood cells' normal physiological temperature.

23. The method of claim 22 wherein the temperature below the red blood cells' normal physiological temperature is from about -10°C to about -193°C.

24. The method of claim 22 wherein the temperature below the red blood cells' normal physiological temperature is about -80°C.

25. A method for storing human red blood cells comprising:

- (a) isolating red blood cells from fresh human blood;
- (b) forming the red blood cell composition of claim 1; and

- 35 -

(c) storing the resulting red blood cell composition at a temperature below normal human physiological temperature effective to preserve the blood cells for a selected period of time.

26. The method of claim 25 wherein the temperature below normal physiological temperature effective to preserve the red blood cells for selected period of time is about -10°C to  
5 -193°C.

27. A method for storing human red blood cells comprising:

(a) isolating red blood cells from fresh human blood;

(b) forming the red blood cell composition of claim 13; and

(c) storing the resulting red blood cell composition at a temperature below normal human  
10 physiological temperature effective to preserve the blood cells for a selected period of time.

28. The method of claim 27 wherein the temperature below normal physiological temperature effective to preserve the red blood cells for selected period of time is about -10°C to  
-193°C.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11674

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A01N 1/02

US CL :435/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 5,919,614 A (LIVESEY et al.) 06 July 1999, see examples.	1-8, 13-20
X,P	US 5,780,295 A (LIVESEY et al.) 14 July 1998, see example 4.	1-28
X	US 5,622,867 A (LIVESEY et al.) 22 April 1997, col. 5 and col. 7.	1-8, 13-20
X	US 5,364,756 A (LIVESEY et al.) 15 November 1994, see example 4.	1-28



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 JULY 1999

Date of mailing of the international search report

29 SEP 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SANDRA SAUCIER

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11674

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RITTMAYER et al. Influence of the cryoprotective agents glycerol and hydroxyethyl starch on red blood cell ATP and 2,3-diphosphoglyceric acid levels. Vox Sanguinis. 1992, Vol. 62, No. 3, pages 141-145, especially abstract.	1-28